Derya Tilki News Today : Breaking News, Live Updates & Top Stories | Vimarsana

ESMO 2023: Delineating Staging Pelvic Lymph Node Dissection Before Radiotherapy and Positioning Primary Prostatectomy

ESMO 2023: Delineating Staging Pelvic Lymph Node Dissection Before Radiotherapy and Positioning Primary Prostatectomy
urotoday.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from urotoday.com Daily Mail and Mail on Sunday newspapers.

United statesDerya tilkiZachary klaassenMartini klinik prostate cancer centerChicago prostate cancer centerGeorgia cancer centerEuropean society of medical oncologyMartini klinik prostate cancerUrologic oncologistAssociate professorMedical oncologyAnnual meetingBiopsy gleason scoreNode procedureOccult nodal metastasesWhole pelvis

PSMA-Targeted Therapy May Decrease PSA Levels in Metastatic Prostate Cancer Subset

Patients with metastatic castration-resistant prostate cancer treated with radioligand therapy, a form of targeted therapy, had improvements in PSA levels and survival with favorable side effect profiles.

United statesNordrhein westfalenDerya tilkiAmerican urological association annual meetingUniversity hospital hamburgMartini klinik prostate cancer centerUrological association annual meetingUniversity hospital hamburg eppendorfProstate cancer

177Lu-PSMA-I&T Demonstrates PSA Responses and a Manageable Toxicity Profile

Radioligand therapy with 177Lu-PSMA-I&T elicited favorable PSA responses and a safety profile similar to PSMA-617.

United statesNordrhein westfalenDerya tilkiAmerican urological association annual meetingMartini klinik prostate cancer centerUniversity hospital hamburgUrological association annual meetingUniversity hospital hamburg eppendorfCommon toxicity criteriaAdverse events177lu psmai amp tPsa responsesProstate cancer

177Lu-PSMA-I&T Generates PSA Responses With Tolerable Safety in mCRPC

Treatment with lutetium 177 PSMA-I&T radioligand therapy led to prostate-specific antigen declines with an acceptable toxicity profile in patients with metastatic castration-resistant prostate cancer.

United statesNordrhein westfalenDerya tilkiMartini klinik prostate cancer centerUniversity hospital hamburgAmerican urological association annual meetingUrological association annualUniversity hospital hamburg eppendorfCommon toxicity criteriaAdverse eventsPatients with metastatic castration resistant prostate cancer177lu psmai amp tKoç university

Initiating Salvage RT When PSA >0 25 ng/mL Linked to All-Cause Mortality

Initiating Salvage RT When PSA >0 25 ng/mL Linked to All-Cause Mortality
renalandurologynews.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from renalandurologynews.com Daily Mail and Mail on Sunday newspapers.

Nordrhein westfalenDerya tilkiUniversity hospital hamburgHealthday newsUniversity hospital hamburg eppendorf